Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- KM Biologics’ COVID-19 Vaccine Approval Likely to Delay into FY2023
November 11, 2022
- Opdivo Nabs Japan Drug Sales Throne for 10th Month: Encise
November 11, 2022
- Japan Ethical Drug Sales Up 4.7% in September: Crecon
November 11, 2022
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- My Linh Kha to Become Interim Chief of Amgen Japan
November 10, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
November 9, 2022
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH
November 8, 2022
- Eisai Begins Talks with US, EU, Japan Regulators towards Lecanemab Submissions; CMS Discussion Now Underway
November 8, 2022
- Cartagena Act Stalls Gene Therapy Development in Japan; Pfizer, FIRM Calling for Deregulation
November 7, 2022
- Parexel Sees Japan as Key Market, Envisions FSP as Growth Pillar
November 7, 2022
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Nichi-Iko to Discontinue Sales of 95 Generics Mainly on Quality Issues
November 4, 2022
- Kissei Grants Taiwan Rights for Linzagolix to Synmosa
November 4, 2022
- Moderna Forging Ahead with mRNA Vaccine Programs for Difficult Viruses; CMV, HIV Jabs in Pipeline: CSO
November 4, 2022
- Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
November 2, 2022
- Takeda Provides Fomepizole to Indonesia to Treat Acute Kidney Injury
November 2, 2022
- Lauren Carey to Serve as Interim President of ViiV Japan
November 2, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…